Inhibition of early tumor growth requires Jα18-positive (natural killer T) cells

Cancer Research

Volumn 63, Issue 12, 2003, Pages 3058-3060

  Stewart, Trina J ^a   Smyth, Mark J ^b   Fernando, Germain J P ^a   Frazer, Ian H ^a   Leggatt, Graham R ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GRAFT; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL ACTIVATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; LYMPHOCYTE DEPLETION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; WART VIRUS;

EID: 0038746593     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Lantz, O., and Bendelac, A. An invariant T cell receptor a chain is used by a unique subset of major histocompatibility complex class I-specific CD4+ and CD4-8-T cells in mice and humans. J. Exp. Med., 180: 1097-1106, 1994.
2. Bendelac, A., Rivera, M. N., Park, S. H., and Roark, J. H. Mouse CD1-specific NK1 T cells: development, specificity, and function. Annu. Rev. Immunol., 15: 535-562. 1997.
3. Terabe, M., Matsui, S., Noben-Trauth, N., Chen, H., Watson, C., Donaldson, D. D., Carbone, D. P., Paul, W. E., and Berzofsky, J. A. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat. Immunol., 1: 511-520, 2000.
4. Crowe, N. Y., Smyth, M. J., and Godfrey. D. I. A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J. Exp. Med. 196: 119-127, 2002.
5. Lin, K. Y., Guamieri, F. G., Staveley-O'Carroll K. F., Levitsky, H. I., August, J. T., Pardoll, D. M., and Wu, T. C. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res., 56: 21-26, 1996.
6. Cui, J., Shin, T., Kawano, T., Sato, H., Kondo, E., Toura, I., Kaneko, Y., Koseki, H., Kanno, M., and Taniguchi, M. Requirement for Vα14 NKT cells in IL-12-mediated rejection of tumors. Science (Wash. DC), 278: 1623-1626, 1997.
7. Fernando. G. J., Murray. B., Zhou, J., and Frazer, I. H. Expression, purification and immunological characterization of the transforming protein E7, from cervical cancer-associated human papigomavims type 16. Clin. Exp. Immunol, 115: 397-403, 1999.
8. Leggatt, G. R., Dunn, L. A., De Kluyver, R. L., Stewart, T., and Frazer, I. H. Interferon-γ enhances cytotoxic T lymphocyte recognition of endogenous peptide in keratinocytes without lowering the requirement for surface peptide. Immunol. Cell Biol., 80: 415-424, 2002.
9. Apostolou, I., Cumano, A., Gachelin, G., and Kourilsky, P. Evidence for two subgroups of CD4 CD8- NKT cells with distinct TCR α β repertoires and differential distribution in lymphoid tissues. J. Immunol, 165: 2481-2490, 2000.
10. Kitamura, H., Iwakabe, K., Yahata, T., Nishimura, S., Ohta, A., Ohmi, Y., Sato, M., Takeda, K., Okumura. K., Van Kaer, L., Kawano, T., Taniguchi, M., and Nishimura. T. The natural killer T (NKT) cell ligand α-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression oil NKT cells. J. Exp. Med., 189: 1121-1128, 1999.
11. Smyth, M. J., Crowe, N. Y., and Godfrey, D. I. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int. Immunol., 13: 459-463, 2001.